Erythromycin before endoscopy improves visualization of the gastric mucosa.

Published Date: 06 Mar 2023

A new study by Diego Adão and team has shown that using erythromycin before the exam can improve your ability to see your vision.

Read Full News

Latest News

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Latest News

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

News All Time

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids Elizabeth Spencer, MD, MS

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

How FDA Approval of SimpleScreen CRC Could Expand Colorectal Cancer Screening With Mark Fendrick, MD Mark Fendrick, MD

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer Alex Hillenbrand

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

C Diff Resistance to Bacitracin Reveals Potential Drug Target

C Diff Resistance to Bacitracin Reveals Potential Drug Target

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

Recommended News For You

CAR T cells improve patients' quality of life: a study

The Benefits of Exercise for Substance Use Disorders.

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

Breast Cancer Incidence Rises in Asian American Women

Prostate cancer screening program beneficial in top decile of polygenic risk score

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

Recommended Articles For You

Hematology Services in Remote Regions: Challenges, Innovations, and Clinical Implications 

Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions 

Molecular Matching for Precision Cancer Therapy 

CAR-T Therapy in Blood Cancers: Mechanisms, Efficacy, and Clinical Integration 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

2.

Dissociative identity disorder: method or fact?

3.

New Gene Therapy Nears EU Nod for Bladder Cancer

4.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

5.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

1.

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide 

2.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

3.

Digital Cancer Caregiver Coordination Platforms: Advances, Clinical Impact, and Future Directions

4.

Community Strategies for Improving Cancer Prevention Literacy

5.

Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Thromboprophylaxis In Medical Settings

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot